These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 27458980)

  • 1. Successful treatment of a disseminated infection with extensively drug-resistant Klebsiella pneumoniae in a liver transplant recipient with a fosfomycin-based multidrug regimen.
    Mills JP; Wilck MB; Weikert BC; Porrett PM; Timko D; Alby K; Bonomo RA; Blumberg EA
    Transpl Infect Dis; 2016 Oct; 18(5):777-781. PubMed ID: 27458980
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Outcomes of critically ill intensive care unit patients treated with fosfomycin for infections due to pandrug-resistant and extensively drug-resistant carbapenemase-producing Gram-negative bacteria.
    Pontikis K; Karaiskos I; Bastani S; Dimopoulos G; Kalogirou M; Katsiari M; Oikonomou A; Poulakou G; Roilides E; Giamarellou H
    Int J Antimicrob Agents; 2014 Jan; 43(1):52-9. PubMed ID: 24183799
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of synergism between colistin, fosfomycin and tigecycline against extended-spectrum β-lactamase-producing Klebsiella pneumoniae isolates or with carbapenem resistance.
    Ku YH; Chen CC; Lee MF; Chuang YC; Tang HJ; Yu WL
    J Microbiol Immunol Infect; 2017 Dec; 50(6):931-939. PubMed ID: 28716360
    [TBL] [Abstract][Full Text] [Related]  

  • 4. High-dose tigecycline and colistin for successful treatment of disseminated carbapenem-resistant Klebsiella pneumoniae infection in a liver transplant recipient.
    Dan JM; Mendler MH; Hemming AW; Aslam S
    BMJ Case Rep; 2014 Nov; 2014():. PubMed ID: 25378111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Outcomes of transplantation using organs from a donor infected with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae.
    Ariza-Heredia EJ; Patel R; Blumberg EA; Walker RC; Lewis R; Evans J; Sankar A; Willliams MD; Rogers J; Milano C; Razonable RR
    Transpl Infect Dis; 2012 Jun; 14(3):229-36. PubMed ID: 22624726
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Ventilator-associated pneumonia caused by colistin-resistant KPC-producing Klebsiella pneumoniae: a case report and literature review.
    Viaggi B; Sbrana F; Malacarne P; Tascini C
    Respir Investig; 2015 May; 53(3):124-8. PubMed ID: 25951099
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Carbapenem-sparing antibiotic regimens for infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae in intensive care unit.
    Sbrana F; Malacarne P; Viaggi B; Costanzo S; Leonetti P; Leonildi A; Casini B; Tascini C; Menichetti F
    Clin Infect Dis; 2013 Mar; 56(5):697-700. PubMed ID: 23155147
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Triple combination antibiotic therapy for carbapenemase-producing Klebsiella pneumoniae: a systematic review.
    Jacobs DM; Safir MC; Huang D; Minhaj F; Parker A; Rao GG
    Ann Clin Microbiol Antimicrob; 2017 Nov; 16(1):76. PubMed ID: 29178957
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Therapeutic strategy for pandrug-resistant Klebsiella pneumoniae severe infections: short-course treatment with colistin increases the in vivo and in vitro activity of double carbapenem regimen.
    Oliva A; Mascellino MT; Cipolla A; D'Abramo A; De Rosa A; Savinelli S; Ciardi MR; Mastroianni CM; Vullo V
    Int J Infect Dis; 2015 Apr; 33():132-4. PubMed ID: 25597275
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of carbapenem-resistant Klebsiella pneumoniae: the state of the art.
    Petrosillo N; Giannella M; Lewis R; Viale P
    Expert Rev Anti Infect Ther; 2013 Feb; 11(2):159-77. PubMed ID: 23409822
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Evaluation of antimicrobial combinations against colistin-resistant carbapenemase (KPC)-producing Klebsiella pneumoniae.
    Maraki S; Papadakis IS
    J Chemother; 2015; 27(6):348-52. PubMed ID: 25248023
    [No Abstract]   [Full Text] [Related]  

  • 12. Mortality Associated with Bacteremia Due to Colistin-Resistant Klebsiella pneumoniae with High-Level Meropenem Resistance: Importance of Combination Therapy without Colistin and Carbapenems.
    Machuca I; Gutiérrez-Gutiérrez B; Gracia-Ahufinger I; Rivera Espinar F; Cano Á; Guzmán-Puche J; Pérez-Nadales E; Natera C; Rodríguez M; León R; Castón JJ; Rodríguez-López F; Rodríguez-Baño J; Torre-Cisneros J
    Antimicrob Agents Chemother; 2017 Aug; 61(8):. PubMed ID: 28559247
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Successful Treatment of Carbapenemase-Producing Pandrug-Resistant Klebsiella pneumoniae Bacteremia.
    Camargo JF; Simkins J; Beduschi T; Tekin A; Aragon L; Pérez-Cardona A; Prado CE; Morris MI; Abbo LM; Cantón R
    Antimicrob Agents Chemother; 2015 Oct; 59(10):5903-8. PubMed ID: 26386029
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fosfomycin for multidrug treatment of Klebsiella pneumoniae carbapenemase bacteremia.
    Kyle JM; Stollings JL; White KD; Noto MJ; Wheeler AP
    Ann Pharmacother; 2015 Mar; 49(3):366-7. PubMed ID: 25691478
    [No Abstract]   [Full Text] [Related]  

  • 15. In vitro activity of the next-generation aminoglycoside plazomicin alone and in combination with colistin, meropenem, fosfomycin or tigecycline against carbapenemase-producing Enterobacteriaceae strains.
    Rodríguez-Avial I; Pena I; Picazo JJ; Rodríguez-Avial C; Culebras E
    Int J Antimicrob Agents; 2015 Dec; 46(6):616-21. PubMed ID: 26391381
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Intravenous fosfomycin for the treatment of nosocomial infections caused by carbapenem-resistant Klebsiella pneumoniae in critically ill patients: a prospective evaluation.
    Michalopoulos A; Virtzili S; Rafailidis P; Chalevelakis G; Damala M; Falagas ME
    Clin Microbiol Infect; 2010 Feb; 16(2):184-6. PubMed ID: 19694767
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Detection and treatment options for Klebsiella pneumoniae carbapenemases (KPCs): an emerging cause of multidrug-resistant infection.
    Hirsch EB; Tam VH
    J Antimicrob Chemother; 2010 Jun; 65(6):1119-25. PubMed ID: 20378670
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Colistin resistance in Klebsiella pneumoniae.
    Ah YM; Kim AJ; Lee JY
    Int J Antimicrob Agents; 2014 Jul; 44(1):8-15. PubMed ID: 24794735
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activity of fosfomycin in combination with imipenem, meropenem, colistin and tigecycline against OXA 48-positive Klebsiella pneumoniae strains.
    Evren E; Azap OK; Çolakoğlu Ş; Arslan H
    Diagn Microbiol Infect Dis; 2013 Jul; 76(3):335-8. PubMed ID: 23726147
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Extended antibiotic resistance in carbapenemase-producing Klebsiella pneumoniae: A case series.
    Walker CD; Shankaran S
    Am J Infect Control; 2016 Sep; 44(9):1050-2. PubMed ID: 27079242
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.